February 13, 2013
At the meeting of ASCO, Hybrigenics report a
completely new aspect to the rapid onset of action of combined
treatment: 43 p. % of patients showing a prostate specific antigen
decreased by at least 30 % within three weeks ). In addition to the
previously indicated high maximum tolerated dose and an excellent
overall response rate , a period of rapid action justifies the
preparation of the next phase of development: the start of a Phase IIb
study.‘As we continue to support high-quality
radiation therapy for each patient in the fight against cancer, AAPM is
committed to identifying and implementing opportunities to improve
safety,’ says Dr. Herman, professor and director of the Division of
Medical Physics at the Department of Radiation Oncology at the Mayo
Clinic. ‘We will achieve this through the performance, improving the
quality of procedures in a practical way for the treatment team, helping
to facilitate uniform, national radiation event reports, and continue
to identify and overcome obstacles to improving safety.
We believe this is the speed of action of inecalcitol
the more remarkable,’ said Dr. Jean-François Dufour-Lamartine,
Hybrigenics Chief Medical Officer. ‘These data suggest that the
anti-proliferative activity of daily inecalcitol effectively completed
the initial cytotoxic effect of Taxotere .’
Hybrigenics , a biopharmaceutical company listed on Alternext in Paris,
with an emphasis on research and development of new therapies, today
announced that the full results of positive Phase IIa studies of daily
oral tolerance inecalcitol neuter clinic patients resistant, in
combination with the standard three-weekly regimen Taxotere ,
chemotherapy will be presented at the annual meeting of the American
Society of Clinical Oncology in Chicago on June 5.
